FDA Alert
09/22/2025
Rebecca Mashaw
Guselkumab becomes the first and only interleukin-23 inhibitor to offer both subcutaneous and intravenous induction of therapy for ulcerative colitis and Crohn's disease.
Guselkumab becomes the first and only interleukin-23 inhibitor to offer both subcutaneous and intravenous induction of therapy for ulcerative colitis and Crohn's disease.
Guselkumab becomes the first and...
09/22/2025
Advances in Inflammatory Bowel Disease Network